Cerebrovascular Risk Factors and Clinical Classification of Strokes

ABSTRACT

Cerebrovascular risk represents a progressive and evolving concept owing to the particular distribution of risk factors in patients with ischemic stroke and in light of the newest stroke subtype classifications that account for pathophysiological, instrumental, and clinical criteria. Age represents the strongest nonmodifiable risk factor associated with ischemic stroke, while hypertension constitutes the most important modifiable cerebrovascular risk factor, confirmed by a host of epidemiological data and by more recent intervention trials of primary (HOT, Syst-Eur, LIFE) and secondary (PROGRESS) prevention of stroke in hypertensive patients.

To be sure, a curious relationship exists between stroke and diabetes. Although the Framingham Study, The Honolulu Heart Program, and a series of Finnish studies reported a linear relationship between improved glucose metabolism and cerebral ischemia, the clinical and prognostic profile of diabetic patients with ischemic stroke remains to be fully understood.

Our group, on the basis of TOAST classification - a diagnostic classification of ischemic stroke developed in 1993 that distinguishes five different clinical subtypes of ischemic stroke: large-artery atherosclerosis (LAAS), cardioembolic infarct (CEI), lacunar infarct (LAC), stroke of other determined origin (ODE), and stroke of undetermined origin (UDE), and now extensively used in clinical and scientific context - analysed the prevalence of cerebrovascular risk factors and the distribution of TOAST subtypes in more 300 patients with acute ischemic stroke in two consecutives studies that reported the significant association between diabetes and the lacunar subtype and a better clinical outcome for diabetic patients, most likely related to the higher prevalence of the lacunar subtype.

Well-confirmed are the roles of cigarette smoking, atrial fibrillation, and asymptomatic carotid stenosis as cerebrovascular risk factors. Particularly interesting seems to be the function of inflammation markers (CRP, TNF-α, IL-1β, ISPs) as potential risk factors. Still elusive remains the association between cholesterol serum levels and stroke, on the basis of the epidemiological data regarding this causative relationship, confirmed only by the results of intervention trials (4S, LIPID, CARE, HPS, ASCOT).

Ultimately, cerebrovascular risk appears peculiar owing to the unique relationship between some modifiable risk factors (mainly diabetes and cholesterol) and the possible preferential association with stroke subtypes and specific cerebrovascular risks.

Stroke - cerebrovascular risk - TOAST Classification

REFERENCES

• 1 Gaddi A, Cicero A, Poli A, Nascetti S, Inzitari D. on behalf of the Italian Group for the Study of Dysmetabolic Diseases and Atherosclerosis . Cerebrovascular disease in Italy and Europe: it is necessary to prevent a pandemic.  J Cardiovasc Risk. 2002;  9 143-145
• 2 Cupples A, D'Agostino R R. Some risk factors related to the incidence of cardiovascular disease and death using pooled repeated biennial measurements: the Framingham Study. 30 year follow-up. In: Kannel W, Wolf P, Garrison R The Framingham Study: An Epidemiological Investigation of Cardiovascular Disease. National Institutes of Health publication 87-2703 Bethesda, MD; National Heart, Lung, and Blood Institute 1987
• 3 Mittelmark M B, Psaty B M, Rautaharju P M, Fried L P, Borhani N O. Prevalence of cardiovascular diseases among older adults. The Cardiovascular Health Study.  Am J Epidemiol. 1993;  137 311-317
• 4 Whisnant J P, Wiebers D O, O’Fallon W M, Sicks J D, Frye R L. A population-based model of risk factors for ischemic stroke: Rochester, Minnesota.  Neurology. 1996;  47 1420-1428
• 5 Jamrozik K, Dobson A, Hobbs M et al.. Monitoring the Incidence of Cardiovascular Disease in Australia. Canberra: Australian Institute of Health and Welfare 2001
• 6 Davis B R, Vogt T, Frost P H, Burlando A, Cohen J. Risk factors for stroke and type of stroke in persons with isolated systolic hypertension.  Stroke. 1998;  29 1333-1340
• 7 Imam I. Stroke: a review with an African perspective.  Ann Trop Med Parasitol. 2002;  96 435-445
• 8 Whittley C Y, Gorelick P B, Raman R, Harris J, Richardson D. Are there differences in risk factor profiles and frequency of CT/MRI-based infarcts among African American stroke patients with and without hypertension? A report from the African American Antiplatelet Stroke Prevention Study (AAASPS).  J Natl Med Assoc. 2003;  95 423-432
• 9 Tiengo A, Del Prato S. Plurimetabolic syndrome: association of diabetes, dyslipidemia, and arterial hypertension [in Italian].  Cardiologia. 1995;  40(12 Suppl 1) 237-243
• 10 MacMahon S, Peto R, Cutler J, Collins R, Sorlie P. Blood pressure, stroke and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias.  Lancet. 1990;  335 765-774
• 11 Collins R, Peto R, MacMahon S, Hebert P, Fiebach N H. Blood pressure, stroke and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context.  Lancet. 1990;  335 827-838
• 12 Tuomilheto J, Rastenyte D, Birkenhanger W et al.. for the Systolic Hypertension in Europe Trial Investigators. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension.  N Engl J Med. 1999;  340 677-684
• 13 Hannsson L, Zanchetti A, Carruthers S G et al.. for the HOT Study Group. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial.  Lancet. 1998;  351 1755-1762
• 14 Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators.  N Engl J Med. 2000;  342 145-153
• 15 PROGRESS collaborative group . Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6.105 individuals with previous stroke or transient ischaemic attack.  Lancet. 2001;  358 1033-1041
• 16 Dahlof B, Devereux B, Kjeldsen S E et al.. for the LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.  Lancet. 2002;  359 995-1003
• 17 Schiffrin E L, Park J B, Intengan H D, Touyz R M. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan.  Circulation. 2000;  101 1653-1659
• 18 Burchfield C M, Curb J D, Rodriguez B L, Abbott R D, Chiu D, Yano K. Glucose intolerance and 22-year stroke incidence. The Honolulu Heart Program.  Stroke. 1994;  25 951-957
• 19 Jorgensen H S, Nakayama H, Raaschou H O, Olsen T S. Stroke in patients with diabetes. The Copenhagen Stroke Study.  Stroke. 1994;  25 1977-1984
• 20 Kuusisto J, Mykkanen L, Pyorala K, Laakso M. Non-insulin-dependent diabetes and its metabolic control are important predictors of stroke in elderly subjects.  Stroke. 1994;  25 1157-1164
• 21 Tuomiletho J, Rastenitè D, Jousilhati P, Sarti C, Vartiainen E. Diabetes mellitus as a risk factor for death from stroke. Prospective study of the middle-aged Finnish population.  Stroke. 1996;  27 210-215
• 22 Lehto S, Ronnemaa T, Pyorala K, Laakso M. Predictors of stroke in middle-aged patients with non-insulin-dependent diabetes.  Stroke. 1996;  27 63-68
• 23 Adler A I, Stratton I M, Neil H AW, Yudkin J S. on behalf of the UK Prospective Diabetes Study Group. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study.  BMJ. 2000;  321 412-419
• 24 Gillett M, Davis W A, Jackson D, Bruce D G, Davis T M. for the Fremantle Diabetes Study. Prospective evaluation of carotid bruit as a predictor of first stroke in type 2 diabetes: the Fremantle Diabetes Study.  Stroke. 2003;  34 2145-2151
• 25 Licata G, Tuttolomondo A, Sinagra D, Pinto A. Diabetes mellitus and stroke [in Italian].  Ital Heart J Suppl. 2002;  3 471-477
• 26 Licata G, Tuttolomondo A, Corrao S, Pinto A. Diabete ed ictus.  Ann Med Intern. 2003;  64-89
• 27 Licata G, Tuttolomondo A, Pinto A. Association between diabetes and stroke subtype on survival and functional outcome 3 months after stroke. Data from the European BIOMED Stroke Project (letter).  Stroke. 2004;  35 e61
• 28 Kernan W N, Inzucchi S E, Viscoli C M, Brass L M, Bravata D M, Horwitz R I. Insulin resistance and risk for stroke.  Neurology. 2002;  59 809-815
• 29 Pyorala M, Miettinen H, Laakso M, Pyorala K. Hyperinsulinemia and the risk of stroke in healthy middle-aged men. The 22-year follow-up results of the Helsinki Policemen Study.  Stroke. 1998;  29 1860-1866
• 30 Beamer N B, Coull B M, Clark W M, Wynn M. Microalbuminuria in ischemic stroke.  Arch Neurol. 1999;  56 699-702
• 31 Guerrero-Romero F, Rodriguez-Moran M. Proteinuria is an independent risk factor for ischemic stroke in non-insulin-dependent diabetes mellitus.  Stroke. 1999;  30 1787-1791
• 32 Konishi M, Iso H, Komachi Y, Iida M, Shimamaoto T. Association of serum total cholesterol, different types of stroke, and stenosis distribution of cerebral arteries. The Akita Pathology Study.  Stroke. 1993;  24 954-964
• 33 Iso H, Jacobs Jr D R, Wentworth D, Neaton J D, Cohen J D. for the MRFIT Research Group. Serum cholesterol levels and six-year mortality from stroke in 350.977 men screened for the Multiple Risk Factor Intervention Trial.  N Engl J Med. 1989;  320 904-910
• 34 Horenstein R B, Smith D E, Mosca L. for the Women Poling Project Investigators. Cholesterol predicts stroke mortality in the Women’s Pooling Project.  Stroke. 2002;  33 1863-1868
• 35 Scandinavian Simvastatin Survival Study Group . Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).  Lancet. 1994;  344 1383-1389
• 36 Plehn J F, Davis B R, Sacks F M et al.. Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study.  Circulation. 1999;  99 216-223
• 37 The Long-tern Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.  N Engl J Med. 1998;  339 1349-1357
• 38 Sheperd J, Cobbe S M, Ford I et al.. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.  N Engl J Med. 1995;  333 1301-1307
• 39 Downs J R, Clearfield M, Weis S et al.. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.  JAMA. 1998;  279 1615-1622
• 40 Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5693 people with diabetes: a randomized placebo-controlled trial.  Lancet. 2003;  361 2005-2016
• 41 Sever P S, Dhalof B, Poulter N R et al.. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.  Lancet. 2003;  361 1149-1158
• 42 Rexrode K M, Hennekens C H, Willet W C et al.. A prospective study of body mass index, weight change and risk of stroke in women.  JAMA. 1997;  277 1539-1545
• 43 Folsom A R, Rasmussen M L, Chambless L E et al.. for the Atherosclerosis Risk in Communities (ARIC) Study Investigators. Prospective associations of fasting insulin, body fat distribution, and diabetes with risk of ischemic stroke.  Diabetes Care. 1999;  22 1077-1083
• 44 Kurth T, Gaziano J M, Berger K et al.. Body mass index and the risk of stroke in men.  Arch Intern Med. 2002;  162 2557-2562
• 45 Letho S, Niskanen L, Ronnemaa T, Laakso M. Serum uric acid is a strong predictor of stroke in patients with non-insulin-dependent diabetes mellitus.  Stroke. 1998;  29 635-639
• 46 Weir C J, Muir S W, Walters M R, Lees K R. Serum urate as an independent predictor of poor outcome and future vascular events after acute stroke.  Stroke. 2003;  34 1951-1956
• 47 Petersen P, Boysen G, Godtfredsen J, Andersen E D, Andersen B. Placebo controlled, randomised trial of warfarin and aspirin prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK Study.  Lancet. 1989;  1 175-179
• 48 The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators . Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study.  JAMA. 1998;  279 1273-1277
• 49 Singer D E, Hughes R A, Gress D R et al.. The effect of aspirin on the risk of stroke in patients with nonrheumatic atrial fibrillation: The BAATAF Study.  Am Heart J. 1992;  124 1567-1573
• 50 Connolly S J, Laupacis A, Gent M, Roberts R S, Cairns J A, Joyner C. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study.  J Am Coll Cardiol. 1991;  18 349-355
• 51 Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five controlled randomized trials.  Arch Intern Med. 1994;  154 1449-1457
• 52 Conway D S, Pearce L A, Chin B S, Hart R G, Lip G Y. Plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 1321 patients with nonvalvular atrial fibrillation. Relationship to stroke risk factors.  Circulation. 2002;  106 1962-1967
• 53 Kaarisalo M M, Immonen-Raiha P, Marttila R J et al.. Atrial fibrillation in older stroke patients: association with recurrence and mortality after first ischemic stroke.  J Am Geriatr Soc. 1997;  45 1297-1301
• 54 Penado S, Cano M, Acha O, Hernandez J L, Riancho J A. Atrial fibrillation as a risk factor for stroke recurrence.  Am J Med. 2003;  114 206-210
• 55 Aronow W S, Ahn C A, Gutsein H. Prevalence of atrial fibrillation and association of atrial fibrillation with prior and new thromboembolic stroke in older patients.  J Am Geriatr Soc. 1996;  44 521-523
• 56 Di Tullio M R, Zwas D R, Sacco R L et al.. Left ventricular mass and geometry and the risk of ischemic stroke.  Stroke. 2003;  34 2380-2384
• 57 Benavente O, Moher D, Pham B. Carotid endarterectomy for asymptomatic carotid stenosis: a meta-analysis.  BMJ. 1998;  317 1477-1480
• 58 Inzitari D, Eliasziw M, Gates P et al.. The causes and risk of stroke in patients with asymptomatic internal-carotid-artery stenosis.  N Engl J Med. 2000;  342 1693-1700
• 59 Nicolaides A, Sabetai M, Kakkos S K et al.. The Asymptomatic Carotid Stenosis and Risk of Stroke (ACSRS) Study. Aims and results of quality control.  Int Angiol. 2003;  22 263-272
• 60 Wolf P A, D’Agostino R B, Kannel W B, Bonita R, Belanger A J. Cigarette smoking as a risk factor for stroke. The Framingham Study.  JAMA. 1988;  259 1025-1029
• 61 Haheim L L, Holme I, Hjermann I, Leren P. Smoking habits and risk of fatal stroke: 18 years follow-up of the Oslo Study.  J Epidemiol Community Health. 1996;  50 621-624
• 62 Yamagishi K, Iso H, Kitamura A et al.. Smoking raises the risk of total and ischemic strokes in hypertensive men.  Hypertens Res. 2003;  26 209-217
• 63 Kawachi I, Colditz G A, Stampfer M J et al.. Smoking cessation and decreased risk of stroke in women.  JAMA. 1993;  269 232-236
• 64 Shaper A, Wannamethee S, Walker M. Pipe and cigar smoking and major cardiovascular events, cancer incidence and all causes mortality in middle-aged British men.  Int J Epidemiol. 2003;  32 802-808
• 65 Jacobs Jr D R, Adachi H, Mulder I et al.. Cigarette smoking and mortality risk: twenty-five-year follow-up of the Seven Countries Study.  Arch Intern Med. 1999;  159 733-740
• 66 Arenillas J F, Alvarez-Sabin J, Molina C A et al.. C-reactive protein predicts further ischemic events in first-episode of transient ischemic attack or stroke patients with intracranial large-artery occlusive disease.  Stroke. 2003;  34 2463-2468
• 67 Sanchez-Moreno C, Dashe J F, Scott T, Thaler D, Folstein M F, Martin A. Decreased levels of plasma vitamin C and increased concentrations of inflammatory and oxidative stress markers after stroke.  Stroke. 2004;  35 163-168
• 68 Lind P, Engstrom G, Stavenow L, Janzon L et al.. Risk of myocardial infarction and stroke in smokers is related to plasma levels of inflammation-sensitive plasma proteins.  Arterioscler Thromb Vasc Biol. 2004;  24 577-582
• 69 Engstrom G, Stavenow L, Hedblad B et al.. Inflammation-sensitive plasma proteins, diabetes, and mortality and incidence of myocardial infarction and stroke: a population based study.  Diabetes. 2003;  52 442-447
• 70 Engstrom G, Lind P, Hedblad B, Stavenow L, Janzon L, Lindgarde F. Effects of cholesterol and inflammation-sensitive plasma proteins on incidence of myocardial infarction and stroke in men.  Circulation. 2002;  105 2632-2637
• 71 Peress N S, Kane W C, Aronson S M. Central nervous system findings in a tenth decade autopsy population.  Prog Brain Res. 1973;  40 473-483
• 72 Kolominsky-Rabas P, Weber M, Gefeller O, Neundoerfer B, Heuschmann U. Epidemiology of ischemic stroke subtyped according to TOAST criteria. Incidence, recurrence, and long term survival in ischemic stroke subtypes: a population-based study.  Stroke. 2001;  32 2735-2740
• 73 Megherbi S E, Milan C, Minier D et al.. Association between diabetes and stroke subtype on survival and functional outcome 3 months after stroke. Data from the European BIOMED Study of Stroke Care Group.  Stroke. 2003;  34 688-694